Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 4/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997208 | 0.87 | SIGMAR1 (0.52) | KCNJ1HRH3SIGMAR1 | |
| SCHEMBL2498540 | 0.82 | IGF1R (0.48) | HRH3SIGMAR1CDK1KDRIGF1R | |
| SCHEMBL2499009 | 0.81 | LTA4H (0.62) | HRH3LTA4H | |
| SCHEMBL1562127 | 0.79 | KCNJ1 (0.82) | KCNJ1HRH3SIGMAR1KCNH2LTA4H | |
| SCHEMBL2500700 | 0.79 | KDM4E (0.65) | SIGMAR1 | |
| SCHEMBL5995769 | 0.76 | SIGMAR1 (0.53) | SIGMAR1 | |
| SCHEMBL4993786 | 0.74 | HRH3 (0.77) | KCNJ1HRH3SIGMAR1KCNH2 | |
| SCHEMBL12190203 | 0.74 | SRC (0.48) | — | |
| SCHEMBL5994744 | 0.73 | KDR (0.46) | HRH3CDK1KDRIGF1RLTA4H | |
| SCHEMBL5997902 | 0.73 | LCK (0.61) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030487-B2 | 2-amino—5-substituted pyrimidine inhibitors | TARGEGEN, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008008234-A1 | 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS | TARGEGEN, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | KCNJ1 2512/4885HRH3 2085/4885SIGMAR1 2661/4885 |
| US-20080027070-A1 | 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS | KDR, FLT4, FLT1 | KCNJ1 4159/4885HRH3 2012/4885SIGMAR1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.